U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H23NO3.ClH
Molecular Weight 349.852
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ETHYLMORPHINE HYDROCHLORIDE

SMILES

Cl.CCOC1=C2O[C@H]3[C@@H](O)C=C[C@H]4[C@H]5CC(C=C1)=C2[C@@]34CCN5C

InChI

InChIKey=ZPPBASOODYCKDP-YZZSNFJZSA-N
InChI=1S/C19H23NO3.ClH/c1-3-22-15-7-4-11-10-13-12-5-6-14(21)18-19(12,8-9-20(13)2)16(11)17(15)23-18;/h4-7,12-14,18,21H,3,8-10H2,1-2H3;1H/t12-,13+,14-,18-,19-;/m0./s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C19H23NO3
Molecular Weight 313.3908
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Ethylmorphine is a derivative of morphine with analgesic and antitussive effect. It acts by activating the opioid receptors and thus has a direct influence on the CNS system. Ethylmorphine was approved in Europe for the treatment of dry cough (Codethyline, Dionine).

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
345.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CODETHYLINE

Approved Use

A cough medicine.
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.09 μM
1.5 mg/kg bw single, oral
dose: 1.5 mg/kg bw
route of administration: Oral
experiment type: SINGLE
co-administered:
ETHYLMORPHINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
222 μM × min
1.5 mg/kg bw single, oral
dose: 1.5 mg/kg bw
route of administration: Oral
experiment type: SINGLE
co-administered:
ETHYLMORPHINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.97 h
1.5 mg/kg bw single, oral
dose: 1.5 mg/kg bw
route of administration: Oral
experiment type: SINGLE
co-administered:
ETHYLMORPHINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
8.5 mg single, oral
Dose: 8.5 mg
Route: oral
Route: single
Dose: 8.5 mg
Sources:
healthy, 10 months
Health Status: healthy
Age Group: 10 months
Sex: M
Sources:
Other AEs: Sedation...
Other AEs:
Sedation (grade 5)
Sources:
1.5 mg/kg single, oral
Dose: 1.5 mg/kg
Route: oral
Route: single
Dose: 1.5 mg/kg
Sources:
healthy, 24 years
Health Status: healthy
Age Group: 24 years
Sex: M
Sources:
Other AEs: Dizziness, Drowsiness...
Other AEs:
Dizziness (7 patients)
Drowsiness (slight, 2 patients)
Loose stools (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Sedation grade 5
8.5 mg single, oral
Dose: 8.5 mg
Route: oral
Route: single
Dose: 8.5 mg
Sources:
healthy, 10 months
Health Status: healthy
Age Group: 10 months
Sex: M
Sources:
Loose stools 1 patient
1.5 mg/kg single, oral
Dose: 1.5 mg/kg
Route: oral
Route: single
Dose: 1.5 mg/kg
Sources:
healthy, 24 years
Health Status: healthy
Age Group: 24 years
Sex: M
Sources:
Dizziness 7 patients
1.5 mg/kg single, oral
Dose: 1.5 mg/kg
Route: oral
Route: single
Dose: 1.5 mg/kg
Sources:
healthy, 24 years
Health Status: healthy
Age Group: 24 years
Sex: M
Sources:
Drowsiness slight, 2 patients
1.5 mg/kg single, oral
Dose: 1.5 mg/kg
Route: oral
Route: single
Dose: 1.5 mg/kg
Sources:
healthy, 24 years
Health Status: healthy
Age Group: 24 years
Sex: M
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer
Drug as victim
PubMed

PubMed

TitleDatePubMed
Characterization of xenobiotic metabolizing enzymes in bovine small intestinal mucosa.
2010-06-01
Bovine liver slices combined with an androgen transcriptional activation assay: an in-vitro model to study the metabolism and bioactivity of steroids.
2010-05
Death of a 10-month-old boy after exposure to ethylmorphine.
2010-03-01
Effect of cytisine on some brain and hepatic biochemical parameters in spontaneously hypertensive rats.
2010-03
[The effect of warfarin was potentiated by an antitussive. Cocillana-Etyfin increased the PK(INR) value].
2009-12-17
[Pharmacological treatment of acute cough].
2009-05-14
Importance of using highly pure internal standards for successful liquid chromatography/tandem mass spectrometric bioanalytical assays.
2009-05
Simultaneous screening and quantification of 25 opioid drugs in post-mortem blood and urine by liquid chromatography-tandem mass spectrometry.
2009-04-15
Determination of opiates and cocaine in urine by high pH mobile phase reversed phase UPLC-MS/MS.
2009-02-01
Purification of CYP2B-like protein from feral leaping mullet (Liza saliens) liver microsomes and its biocatalytic, molecular, and immunological characterization.
2008-08-30
Inhibitory effects of opioids on compound action potentials in frog sciatic nerves and their chemical structures.
2008-08-01
Determining plasma morphine levels using GC-MS after solid phase extraction to monitor drug levels in the postoperative period.
2008-06
Error in the article: "driving under the influence of opiates: concentration relationships between morphine, codeine, 6-acetyl morphine, and ethyl morphine in blood".
2008-06
Driving under the influence of opiates: concentration relationships between morphine, codeine, 6-acetyl morphine, and ethyl morphine in blood.
2008-05
[Study of cytotoxic and antiviral effects of some eye drops].
2008
A hybrid FIA/HPLC system incorporating monolithic column chromatography.
2007-09-26
Validation of direct injection electrospray LC-MS/MS for confirmation of opiates in urine drug testing.
2007-07
Electrospray LC-MS method with solid-phase extraction for accurate determination of morphine-, codeine-, and ethylmorphine-glucuronides and 6-acetylmorphine in urine.
2007-03
[Current problems in the quality control of pharmaceutical preparations manufactured in pharmacies II. Paracetamol contraining preparations].
2006
Automated multiple development thin-layer chromatography for separation of opiate alkaloids and derivatives.
2005-07-08
Validated toxicological determination of 30 drugs of abuse as optimized derivatives in oral fluid by long column fast gas chromatography/electron impact mass spectrometry.
2005-06
Inhibition of rat liver CYP2D in vitro and after 1-day and long-term exposure to neuroleptics in vivo-possible involvement of different mechanisms.
2005-01
Screening for drugs of abuse in hair with ion spray LC-MS-MS.
2004-10-29
Expression and characterization of human cytochrome P450 4F11: Putative role in the metabolism of therapeutic drugs and eicosanoids.
2004-09-15
Evaluation of the One-Step ELISA kit for the detection of buprenorphine in urine, blood, and hair specimens.
2004-07-16
Biochemical background of toxic interaction between tiamulin and monensin.
2004-03-15
Interpretation of the presence of 6-monoacetylmorphine in the absence of morphine-3-glucuronide in urine samples: evidence of heroin abuse.
2003-10
Genomic characterization and regulation of CYP3a13: role of xenobiotics and nuclear receptors.
2003-09
Enzyme immunoassay validation for the detection of buprenorphine in urine.
2003-03
Evidence for the presence of active cytochrome P450 systems in Schistosoma mansoni and Schistosoma haematobium adult worms.
2002-05-22
Simultaneous determination of codeine and ethyl morphine HCL in tablet formulations using LC.
2001-08
[Experimental study on using diclofenac sodium or dionine topically to treat fibrinous membrane after intraocular lens implantation].
2001-06-28
Effects of fumonisin B1 present in Fusarium moniliforme culture material on drug metabolising enzyme activities in ducks.
2001-05-19
[Effects of diclofenac sodium combined with dionine in cases with fibrinous membrane after intraocular lens implantation].
2001-04-28
Effects of ethanol on ethylmorphine metabolism in isolated rat hepatocytes: characterization by means of a multicompartmental model.
1997-04
Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose.
1995-06
Acute renal failure due to concomitant action of methotrexate and indomethacin.
1986-06-14
Patents

Sample Use Guides

The recommended dose in adults is 50 mg of codethyline per day, i.e. 10 tablets (1 tablet contains 5 mg of ethylmorphine hydrochloride) per day over several intakes, at a minimum of 4 hours apart. In children the normal dose is 1 tablet per intake, to be renewed after 6 hours if necessary, without exceeding 4 tablets per day.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:11:26 GMT 2025
Edited
by admin
on Mon Mar 31 18:11:26 GMT 2025
Record UNII
MFM5450P3T
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ETHYLMORPHINE HYDROCHLORIDE
EP   MI   WHO-DD  
Common Name English
CODETHYLINE HYDROCHLORIDE
Preferred Name English
Ethylmorphine hydrochloride [WHO-DD]
Common Name English
ETHYLMORPHINE HCL
Common Name English
(5.ALPHA.,6.ALPHA.)-7,8-DIDEHYDRO-4,5-EPOXY-3-ETHOXY-17-METHYLMORPHINAN-6-OL HYDROCHLORIDE
Systematic Name English
ETHYLMORPHINE HYDROCHLORIDE ANHYDROUS [MI]
Common Name English
ETHYLMORPHINE HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C67413
Created by admin on Mon Mar 31 18:11:26 GMT 2025 , Edited by admin on Mon Mar 31 18:11:26 GMT 2025
Code System Code Type Description
PUBCHEM
5360692
Created by admin on Mon Mar 31 18:11:26 GMT 2025 , Edited by admin on Mon Mar 31 18:11:26 GMT 2025
PRIMARY
CAS
125-30-4
Created by admin on Mon Mar 31 18:11:26 GMT 2025 , Edited by admin on Mon Mar 31 18:11:26 GMT 2025
PRIMARY
SMS_ID
100000092080
Created by admin on Mon Mar 31 18:11:26 GMT 2025 , Edited by admin on Mon Mar 31 18:11:26 GMT 2025
PRIMARY
ChEMBL
CHEMBL1712170
Created by admin on Mon Mar 31 18:11:26 GMT 2025 , Edited by admin on Mon Mar 31 18:11:26 GMT 2025
PRIMARY
DRUG BANK
DBSALT002363
Created by admin on Mon Mar 31 18:11:26 GMT 2025 , Edited by admin on Mon Mar 31 18:11:26 GMT 2025
PRIMARY
NCI_THESAURUS
C76842
Created by admin on Mon Mar 31 18:11:26 GMT 2025 , Edited by admin on Mon Mar 31 18:11:26 GMT 2025
PRIMARY
RXCUI
235782
Created by admin on Mon Mar 31 18:11:26 GMT 2025 , Edited by admin on Mon Mar 31 18:11:26 GMT 2025
PRIMARY RxNorm
MERCK INDEX
m5154
Created by admin on Mon Mar 31 18:11:26 GMT 2025 , Edited by admin on Mon Mar 31 18:11:26 GMT 2025
PRIMARY
ECHA (EC/EINECS)
204-734-4
Created by admin on Mon Mar 31 18:11:26 GMT 2025 , Edited by admin on Mon Mar 31 18:11:26 GMT 2025
PRIMARY
EPA CompTox
DTXSID70924986
Created by admin on Mon Mar 31 18:11:26 GMT 2025 , Edited by admin on Mon Mar 31 18:11:26 GMT 2025
PRIMARY
FDA UNII
MFM5450P3T
Created by admin on Mon Mar 31 18:11:26 GMT 2025 , Edited by admin on Mon Mar 31 18:11:26 GMT 2025
PRIMARY
EVMPD
SUB13767MIG
Created by admin on Mon Mar 31 18:11:26 GMT 2025 , Edited by admin on Mon Mar 31 18:11:26 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
SOLVATE->ANHYDROUS
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY